In conclusion, this study is the first to reveal the pathophysiological roles of GPA in hepatic steatosis at the cellular and animal levels, suggesting the potential therapeutic applications of GPA in NAFLD and obesity-related metabolic diseases. The gene discussed is GYPA; the disease is metabolic disease.